Trinity Biotech

Trinity Biotech Debt/Market Cap

The Debt to Market Capitalization Ratio of Trinity Biotech (TRIB) as of Nov 10, 2026 is 961.78 %. In the previous year, Debt to Market Capitalization Ratio was 702.35 % — a change of 36.94% (higher).

Debt/Market Cap

961.78 %

YoY

36.94%

Last updated:

Debt to Market Capitalization Ratio of Trinity Biotech is 2025 961.78 % . Debt to Market Capitalization Ratio of Trinity Biotech was 2024 702.35 % . It decreases by 36.94% higher compared to the previous year.

The Trinity Biotech Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
571.95 USD
Jan 1, 2019
712.15 USD
Jan 1, 2020
727.28 USD
Jan 1, 2021
691.15 USD
Jan 1, 2022
503.25 USD
Jan 1, 2023
469.98 USD
Jan 1, 2024
702.35 USD
Jan 1, 2025
961.78 USD
The Trinity Biotech Debt/Market Cap history
YEARDebt/Market CapYoY
961.78 %+36.94%
702.35 %+49.44%
469.98 %-6.61%
503.25 %-27.19%
691.15 %-4.97%
727.28 %+2.12%
712.15 %+24.51%
571.95 %-13.79%
663.42 %-1.64%
674.47 %-1.31%
683.39 %+595.50%
98.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Debt to Market Capitalization Ratio of Trinity Biotech is 961.78 % in 2025.

Debt to Market Capitalization Ratio of Trinity Biotech changed from 702.35 % to 961.78 %, representing a 36.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Trinity Biotech

All Key Metrics — Trinity Biotech